January #98 : CMV Drug Does Double Duty - by Mike Barr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

10 Ways to End AIDS (in 10 years)

Happy New You

Political Science

"Prevention" for Positives

Habitats for HIVers

On the Job

Going Under Cover

All the Right Places

2024: AIDS Cured, ex-PWAs Ignored

Trouble Indemnity

Earthwatch

Show & Gel

Healthful Humor

Living on Hope

Milestones

High Resolution: New Year’s Creeds

2004: What’s In, What’s Out?

Briefs

When Your CD4s Count

New Med on the Shelf

Quick Study: Virus in Vaginas

Strike a Pose

Chicago Hope?

Quick Study: Hep C

Watch Your Mouth

2X

CMV Drug Does Double Duty

Bed Head

Unreality TV

Mailbox

Publisher's Letter

Amazing Race



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January 2004

CMV Drug Does Double Duty

by Mike Barr

Foscarnet (foscavir), the pricey drug for cytomegalovirus (CMV) and other herpes viruses (like that pesky genital variety), had its rise to stardom halted by the hassle of a daily IV drip—and nasty side effects (kidney problems, fever, rash, dizziness). But it’s still giving the potentially blinding CMV a run for its money—and a few clever clinicians say salvage combos often perform better with foscarnet on board. While docs may prescribe the med for CMV or drug-resistant herpes (HSV), their patients get the benefit of an extra HIV-fighting machine.

New York City HIV pro Trip Gulick, MD, explains that foscarnet may block the part of HIV reproduction that escapes the nukes. HIV, a mouse in a maze, tries to evade a triple or quadruple combo—and foscarnet stands in the only remaining exit.

“I know a few docs who’ve been doing this for decades,” says Project Inform’s Martin Delaney. “They bring in Foscavir for people who’ve failed all else or have just one drug left.” Most doctors interviewed would not suggest using foscarnet for its antiretroviral powers alone. Both Gulick and Howard Grossman, MD, say it’s too hard to administer—and its side effects too hard to take—to use as a salvage drug, unless it’s needed to treat CMV or HSV.

Meanwhile, Gulick has a patient with resistant HIV whose viral load fell dramatically after starting a new combo—plus Foscavir for acyclovir-resistant herpes. His virus rebounded when the foscarnet, but not the HIV meds, was stopped. “This doesn’t prove that foscarnet caused the drop in viral load,” Gulick cautions, “but it is interesting.”




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    InDefaultOf
    Seattle
    Washington


    pevans
    San Francisco
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.